Cargando…

Cell Entry of Enveloped Viruses

Enveloped viruses penetrate their cell targets following the merging of their membrane with that of the cell. This fusion process is catalyzed by one or several viral glycoproteins incorporated on the membrane of the virus. These envelope glycoproteins (EnvGP) evolved in order to combine two feature...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosset, François-Loic, Lavillette, Dimitri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149602/
https://www.ncbi.nlm.nih.gov/pubmed/21310296
http://dx.doi.org/10.1016/B978-0-12-380860-8.00004-5
_version_ 1783520841005268992
author Cosset, François-Loic
Lavillette, Dimitri
author_facet Cosset, François-Loic
Lavillette, Dimitri
author_sort Cosset, François-Loic
collection PubMed
description Enveloped viruses penetrate their cell targets following the merging of their membrane with that of the cell. This fusion process is catalyzed by one or several viral glycoproteins incorporated on the membrane of the virus. These envelope glycoproteins (EnvGP) evolved in order to combine two features. First, they acquired a domain to bind to a specific cellular protein, named “receptor.” Second, they developed, with the help of cellular proteins, a function of finely controlled fusion to optimize the replication and preserve the integrity of the cell, specific to the genus of the virus. Following the activation of the EnvGP either by binding to their receptors and/or sometimes the acid pH of the endosomes, many changes of conformation permit ultimately the action of a specific hydrophobic domain, the fusion peptide, which destabilizes the cell membrane and leads to the opening of the lipidic membrane. The comprehension of these mechanisms is essential to develop medicines of the therapeutic class of entry inhibitor like enfuvirtide (Fuzeon) against human immunodeficiency virus (HIV). In this chapter, we will summarize the different envelope glycoprotein structures that viruses develop to achieve membrane fusion and the entry of the virus. We will describe the different entry pathways and cellular proteins that viruses have subverted to allow infection of the cell and the receptors that are used. Finally, we will illustrate more precisely the recent discoveries that have been made within the field of the entry process, with a focus on the use of pseudoparticles. These pseudoparticles are suitable for high-throughput screenings that help in the development of natural or artificial inhibitors as new therapeutics of the class of entry inhibitors.
format Online
Article
Text
id pubmed-7149602
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71496022020-04-13 Cell Entry of Enveloped Viruses Cosset, François-Loic Lavillette, Dimitri Adv Genet Article Enveloped viruses penetrate their cell targets following the merging of their membrane with that of the cell. This fusion process is catalyzed by one or several viral glycoproteins incorporated on the membrane of the virus. These envelope glycoproteins (EnvGP) evolved in order to combine two features. First, they acquired a domain to bind to a specific cellular protein, named “receptor.” Second, they developed, with the help of cellular proteins, a function of finely controlled fusion to optimize the replication and preserve the integrity of the cell, specific to the genus of the virus. Following the activation of the EnvGP either by binding to their receptors and/or sometimes the acid pH of the endosomes, many changes of conformation permit ultimately the action of a specific hydrophobic domain, the fusion peptide, which destabilizes the cell membrane and leads to the opening of the lipidic membrane. The comprehension of these mechanisms is essential to develop medicines of the therapeutic class of entry inhibitor like enfuvirtide (Fuzeon) against human immunodeficiency virus (HIV). In this chapter, we will summarize the different envelope glycoprotein structures that viruses develop to achieve membrane fusion and the entry of the virus. We will describe the different entry pathways and cellular proteins that viruses have subverted to allow infection of the cell and the receptors that are used. Finally, we will illustrate more precisely the recent discoveries that have been made within the field of the entry process, with a focus on the use of pseudoparticles. These pseudoparticles are suitable for high-throughput screenings that help in the development of natural or artificial inhibitors as new therapeutics of the class of entry inhibitors. Elsevier Inc. 2011 2011-02-08 /pmc/articles/PMC7149602/ /pubmed/21310296 http://dx.doi.org/10.1016/B978-0-12-380860-8.00004-5 Text en Copyright © 2011 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Cosset, François-Loic
Lavillette, Dimitri
Cell Entry of Enveloped Viruses
title Cell Entry of Enveloped Viruses
title_full Cell Entry of Enveloped Viruses
title_fullStr Cell Entry of Enveloped Viruses
title_full_unstemmed Cell Entry of Enveloped Viruses
title_short Cell Entry of Enveloped Viruses
title_sort cell entry of enveloped viruses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149602/
https://www.ncbi.nlm.nih.gov/pubmed/21310296
http://dx.doi.org/10.1016/B978-0-12-380860-8.00004-5
work_keys_str_mv AT cossetfrancoisloic cellentryofenvelopedviruses
AT lavillettedimitri cellentryofenvelopedviruses